title: Intestinal CYP3A4 is not involved in the enantioselective disposition of lansoprazole.
abstract: The contribution of (S)-lansoprazole to CYP3A4-catalysed sulfoxidation is greater than that of (R)-lansoprazole. The aim was to investigate the effect of grapefruit juice on the enantioselective disposition of lansoprazole among three CYP2C19 genotype groups. Eighteen healthy subjects, consisting of six each of homozygous extensive metabolizers (homEMs), heterozygous extensive metabolizers (hetEMs) and poor metabolizers (PMs), ingested a single oral dose of 60 mg racemic lansoprazole after taking either 200 ml grapefruit juice or water. There was no effect of grapefruit juice on the mean maximum plasma concentrations (C(max)) or the elimination half-life for each lansoprazole enantiomer in all three CYP2C19 genotype groups. Similarly, the pharmacokinetic parameters of lansoprazole sulfone remained unaltered by grapefruit juice in all three groups. The CYP3A4-mediated first-pass sulfoxidation of (R)- and (S)-lansoprazole were not influenced by grapefruit juice. In addition, stereoselectivity of the intestinal CYP3A4-catalysed sulfoxidation of (R)- and (S)-lansoprazole was not observed.
authors.affiliation: Department of Pharmacy, Akita University Hospital, Akita, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Miura
authors.forename: H
authors.initials: H
authors.lastname: Kagaya
authors.forename: H
authors.initials: H
authors.lastname: Tada
authors.forename: T
authors.initials: T
authors.lastname: Uno
authors.forename: N
authors.initials: N
authors.lastname: Yasui-Furukori
authors.forename: T
authors.initials: T
authors.lastname: Tateishi
authors.forename: T
authors.initials: T
authors.lastname: Suzuki
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000284:Administration, Oral; D000328:Adult; D001628:Beverages; D032083:Citrus paradisi / Q000737:chemistry*; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D064748:Dexlansoprazole; D005260:Female; D006801:Humans; D007422:Intestines / Q000187:drug effects / Q000201:enzymology*; D064747:Lansoprazole; D008297:Male; D008657:Metabolic Clearance Rate / Q000187:drug effects; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D013237:Stereoisomerism
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D064747:Lansoprazole; D003577:Cytochrome P-450 Enzyme System; C581535:Lansoprazole Sulfone; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D009853:Omeprazole; D064748:Dexlansoprazole